We are enclosing Audited Financial Results for the Quarter ended 31st march , 2026 which are approved in Board Meeting which was held today i.e Wednesday, 27th Day of May, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Godavari Drugs Limited reported audited FY26 results with revenue declining 6.7% to ₹10,580.81 Lakhs from ₹11,335.01 Lakhs in FY25. Net profit fell 6.6% to ₹408.91 Lakhs from ₹438.00 Lakhs, with basic EPS at ₹5.43 vs ₹5.82 prior year. The company raised ₹4,411.73 Lakhs via preferential allotment in March 2026, which was fully deployed towards capital expenditure for pharmaceutical manufacturing expansion (₹1,000 Lakhs), working capital (₹1,711.73 Lakhs), and repayment of promoter/director unsecured loans (₽1,600 Lakhs). Operating cash flow sharply deteriorated to ₹73.36 Lakhs from ₹1,119.60 Lakhs in FY25. Inventories increased to ₹4,606.41 Lakhs from ₹2,794.13 Lakhs. Related party transactions totaling ₹376.32 Lakhs included loans to directors (₹273 Lakhs), remuneration, rent, and interest payments. Statutory auditors M/s Ayyadevara & Co. issued an unmodified (clean) opinion.
Revenue and profit decline along with sharply reduced operating cash flow are concerning for shareholders, though the clean audit opinion and successful capital raise for expansion provide some support. The company appears to be in an investment phase with significant inventory buildup and working capital deployment.